News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis Pharma AG (NVS) Obtains Rights From Otsuka Pharmaceutical Co., Ltd. To Develop New Treatment For Dry Eye


10/19/2005 5:12:38 PM

BASEL, Switzerland, Feb. 7, 2005 (PRIMEZONE) -- Novartis announced today that it has in-licensed rebamipide, an investigational treatment for dry eye, from Otsuka Pharmaceutical Company, Ltd. Currently being tested in two Phase III studies in the U.S., rebamipide is expected to demonstrate a novel mechanism of action to enhance tear secretion and increase the levels of mucin covering the conjunctiva and cornea of the eye.

Read at Prime Zone

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES